What is HC Wainwright’s Forecast for AnaptysBio Q1 Earnings?
Research analysts at HC Wainwright dropped their Q1 2025 EPS estimates for AnaptysBio in a research report issued on ...
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $51.00
AnaptysBio (NASDAQ:ANAB – Free Report) had its price target boosted by Wells Fargo & Company from $40.00 to $51.00 in a report issued on Thursday,Benzinga reports. Wells Fargo & Company currently has ...
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral
H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...
AnaptysBio price target raised to $51 from $40 at Wells Fargo
Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
The Pharma Letter5d
AnaptysBio rockets on rosnilimab data
Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...
Anaptys surges as arthritis therapy succeeds in mid-stage trial
AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial
AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...